Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes

doi:10.1016/S0140-6736(94)90817-6

The Lancet

Volume 343, Issue 8889, 8 January 1994, Pages 85-86

https://doi.org/10.1016/S0140-6736(94)90817-6 Get rights and content

Abstract

We have observed five children with cystic fibrosis, who presented over 2 months, with meconium ileus equivalent that falled to respond to medical management. At surgery, four had a stricture in the ascending colon, and all had histopathological changes of post-ischaemic ulceration repair, with mucosal and submucosal fibrosis. The only common change in the management of these children was a switch from conventional enteric-coated pancreatic enzymes to high-strength products 12–15 months befire presentation.

References (6)

Jw Mateshe et al.
Meconium ileus equivalent complicating cystic fibrosis in postneonatal children and young adults: report of 12 cases
Gastroenterology
(1977)
S. O'Halloran et al.
Gastrografin in acute meconium ileus equivalent
Arch Dis Child
(1986)

There are more references available in the full text version of this article.

Cited by (261)

Incidence of fibrosing colonopathy with pancreatic enzyme replacement therapy in patients with cystic fibrosis
2023, Journal of Cystic Fibrosis
High daily doses of pancreatic enzyme replacement therapy (PERT) were historically associated with risk of fibrosing colonopathy (FC) in people with cystic fibrosis (pwCF), leading to development of PERT dosing guidelines and reformulated products. This study quantified incidence of FC in pwCF treated with PERT following those measures.
This large prospective cohort study included eligible pwCF enrolled in the Cystic Fibrosis Foundation Patient Registry with ≥1 clinic visit in 2012–2014 and follow-up through 2020. Data on PERT exposure, demographics, and medical history were collected. Clinical data, imaging, and histopathology of suspected cases were examined by an independent adjudication panel of physicians familiar with this complication.
Base Study Population included 26,025 pwCF who contributed 155,814 person-years [mean (SD) 6.0 (2.0) years] of follow-up. Over 7.8 years, 29 pwCF had suspected FC; three cases were confirmed by adjudication, 22 cases were confirmed as not FC, and four cases were indeterminate. There were 22,161 pwCF exposed to any PERT, with mean PERT use time of 5.583 person-years and mean daily dose of 8328 U lipase per kg per day. All three confirmed cases and four indeterminate cases of FC occurred during current use of PERT. Incidence rates per 1000 person-years exposed were 0.0242 (95 % CI [0.0050, 0.0709]) for confirmed FC and 0.0566 (95 % CI [0.0227, 0.1166]) for indeterminate or confirmed FC.
The incidence of FC in pwCF is very low in the era of current treatment guidelines and more stringent quality standards for PERT products.
Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators
2022, Paediatric Respiratory Reviews
Cystic fibrosis (CF) – although primarily a lung disease – also causes a variety of gastrointestinal manifestations which are important for diagnosis, prognosis and quality of life. All parts of the gastrointestinal tract can be affected by CF. Besides the well-known pancreatic insufficiency, gastroesophageal reflux disease, liver disease and diseases of the large intestine are important pathologies that impact on prognosis and also impair quality of life. Diagnosis and management of gastrointestinal manifestations will be discussed in this review. Since optimisation of CF therapy is associated with a significantly longer life-span of CF patients nowadays, also gastrointestinal malignancies, which are more common in CF than in the non-CF population need to be considered. Furthermore, novel evidence on the role of the gut microbiome in CF is emerging. The introduction of cystic fibrosis transmembrane conductance regulator (CFTR) protein modulators gives hope for symptom alleviation and even cure of gastrointestinal manifestations of CF.
Cystic Fibrosis Therapies
2021, Encyclopedia of Respiratory Medicine, Second Edition
Cystic fibrosis (CF) is a multi-system genetic disorder. Therapies are primarily focused on preserving lung function and nutrition from childhood through to adulthood. Early detection and effective clinical management of CF is key to limiting disease progression (Bell et al., 2020; Sermet-Gaudelus et al., 2011). Chronic illnesses carry high treatment burden and therefore it is essential that treatments are rationalized where possible.
This article will outline the therapies used to prevent CF disease progression and therapies used for disease complications. The use of therapies for the basic defect of CF will be discussed in another chapter.
Inflammatory bowel disease–like conditions: medication-induced enteropathy
2020, Atlas of Endoscopy Imaging in Inflammatory Bowel Disease
A variety of medications can cause ulcerative or nonulcerative inflammation throughout the gastrointestinal (GI) tract. The long-term use of some of the agents can even cause strictures and perforation. Clinical, endoscopic, histologic, and radiographic features of drug-induced GI injury can mimic that in inflammatory bowel disease (IBD). In addition, some of these medications are used in patients with IBD for the treatment of IBD-associated complications or other comorbidities. Differential diagnosis of IBD, medication-associated GI injury, and superimposed drug-induced injury in IBD are critical for the management and prognosis. Endoscopy with biopsy along with clinical history is critical for the diagnosis and differential diagnosis.
Pancreatic insufficiency in Cystic Fibrosis
2017, Journal of Cystic Fibrosis
Citation Excerpt :
Some providers and patients have suggested that PERT can cause constipation, but studies have not supported this [77]. In the early 1990′s, a life-threatening entity termed fibrosing colonopathy affected a small number of CF patients [78–80]. Individuals with this condition developed abdominal pain, diarrhea, and evidence of intestinal obstruction.
Gastrointestinal, Pancreatic, and Hepatobiliary Manifestations of Cystic Fibrosis
2016, Pediatric Clinics of North America

View all citing articles on Scopus

View full text

Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes

Abstract

Meconium ileus equivalent complicating cystic fibrosis in postneonatal children and young adults: report of 12 cases

Gastroenterology

Gastrografin in acute meconium ileus equivalent

Arch Dis Child